Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease

Gut

Volumn 49, Issue 2, 2001, Pages 303-308

  Vlachogiannakos, J ^a   Tang, A K W ^a   Patch, D ^a   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; IRBESARTAN; LOSARTAN; SARALASIN;

CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHRONIC DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; SODIUM;

EID: 0034922565     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.2.303     Document Type: Review

References (53)

1. Hepatic venous pressure: An old test as a new prognostic marker in cirrhosis?
2. Pharmacological treatment of portal hypertension: Present and future
3. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension
4. Primary prophylaxis for portal hypertensive bleeding in cirrhosis
5. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A final report
6. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
7. Short-term effects of propranolol on portal venous pressure
8. The pericyte - A review
9. Hepatic stellate cells and the regulation of liver inflammation
10. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin, and nitric oxide
11. The renin-angiotensin system in liver disease
12. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites
13. The role of vasoactive mediators in portal hypertension
14. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver
15. Angiotensin receptors and their antagonists
16. Fat-storing cells as liver specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients
17. Hypotensive agents and pressor substances: The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man
18. Clinical pharmacology of ACE inhibition
19. Angiotensin II receptor antagonists
20. Effect of losartan, an angiotensin II receptor antagonist, on the portal pressure in cirrhosis
21. Efficacy of irbesartan, an angiotensin II receptor selective antagonist, in the treatment of portal hypertension
22. Intrapatient comparison of acute hemodynamic, hormonal, and natriuretic responses to captopril versus enalapril in liver cirrhosis
23. Acute effect of captopril on systemic and renal haemodynamics and on renal function in cirrhotic patients with ascites
24. Effect of captopril on renal function in patients with cirrhosis and ascites
25. Effect of low-dose captopril on renal haemodynamics and function in patients with cirrhosis of liver
26. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis
27. Angiotensin antagonist in liver disease
28. Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites
29. Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis
30. Efficay of low-dose captopril in addition to frusemide and spirololactone in patients with decompensated liver disease during blunt diuresis
31. Adverse effects of captopril in treatment of resistant ascites, a state of functional bilateral renal artery stenosis
32. Effect of captopril on renal functions, renal and portal haemodynamics in patients with cirrhosis
33. Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites
34. Role of routine estimation of creatinine clearance in patients with liver cirrhosis
35. Peripheral arterial vasodilatation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
36. Control of glomerular filtration rate by renin-angiotensin system
37. Renin-angiotensin in preascitic cirrhosis: Evidence for primary peripheral arterial vasodilatation
38. The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis
39. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis
40. Effect of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis
41. Haemodynamic effect of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis
42. Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic haemodynamics in portal hypertension
43. Hormonal and metabolic effects of angiotensin converting enzymes inhibitors. Possible differences between enalapril and captopril
44. Effect of angiotensin-converting enzyme inhibition on circulating and local kinins levels
45. Effect of angiotensin II blockade on systemic and hepatic hemodynamics and on renin-angiotensin-aldosterone system in cirrhosis with ascites
46. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution
47. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
48. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators
49. The angiotensin II receptor antagonist irbesartan for the treatment of portal hypertension: A placebo controlled, double-blind study
50. Angiotensin II induces contraction and proliferation of human hepatic stellate cells
51. Endothelin induced contractility of stellate cells from normal and cirrhotic liver: Implications for regulation of portal pressure and resistance
52. Tissue-specific regulation of growth factors and clusterin by angiotensin II
53. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: Implications for therapy